Clinical efficacy of 60-mg dexlansoprazole and 40-mg esomeprazole after 24 weeks for the on-demand treatment of gastroesophageal reflux disease grades A and B: a prospective randomized trial

Hung-Hsien Chiang, Deng-Chyang Wu, Pin-I Hsu, Chao-Hung Kuo, Wei-Chen Tai, Shih-Cheng Yang, Keng-Liang Wu, Chih-Chien Yao, Cheng-En Tsai, Chih-Ming Liang, Yao-Kuang Wang, Jiunn-Wei Wang, Chih-Fang Huang, Seng-Kee Chuah, Taiwan Acid-Related Disease Study Group, Hung-Hsien Chiang, Deng-Chyang Wu, Pin-I Hsu, Chao-Hung Kuo, Wei-Chen Tai, Shih-Cheng Yang, Keng-Liang Wu, Chih-Chien Yao, Cheng-En Tsai, Chih-Ming Liang, Yao-Kuang Wang, Jiunn-Wei Wang, Chih-Fang Huang, Seng-Kee Chuah, Taiwan Acid-Related Disease Study Group

Abstract

Purpose: Research comparing the clinical efficacy of dexlansoprazole and esomeprazole has been limited. This study aims to compare the clinical efficacy of single doses of dexlansoprazole (modified-release 60 mg) and esomeprazole (40 mg) after 24-week follow-up in patients with mild erosive esophagitis. Methods: We enrolled 86 adult GERD subjects, randomized in a 1:1 ratio to two sequence groups defining the order in which they received single doses of dexlansoprazole (n=43) and esomeprazole (n=43) for 8 weeks as initial treatment. Patients displaying complete symptom resolution (CSR) by the end of initial treatment (8 weeks) were switched to on-demand therapy until the end of 24 weeks. Follow-up endoscopy was performed either at the end of 24 weeks or when severe reflux symptoms occurred. Five patients were lost to follow-up, leaving 81 patients (dexlansoprazole, n=41; esomeprazole, n=40) in the per-protocol analysis. Results: The GERDQ scores at 4-, 8-, 12-, 16-, 20-, and 24-week posttreatment were less than the baseline score. The CSR, rate of symptom relapse, days to symptom resolution, sustained healing rate of erosive esophagitis, treatment failure rate, and the number of tablets taken in 24 weeks were similar in both groups. The esomeprazole group had more days with reflux symptoms than the dexlansoprazole group (37.3±37.8 vs 53.9±54.2; P=0.008). In the dexlansoprazole group, patients exhibited persistent improvement in the GERDQ score during the on-demand period (week 8 vs week 24; P<0.001) but not in the esomeprazole group (week 8 vs week 24; P=0.846). Conclusions: This study suggests that the symptom relief effect for GERD after 24 weeks was similar for dexlansoprazole and esomeprazole. Dexlansoprazole exhibited fewer days with reflux symptoms in the 24-week study period, with better persistent improvement in the GERDQ score in the on-demand period. (ClinicalTrials. gov number: NCT03128736).

Keywords: 24-week response; GERDQ score; dexlansoprazole; esomeprazole; gastroesophageal reflux disease; on-demand.

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
The schematic flowchart of the study design. Abbreviations: ITT, intent-to-treat; PP, per-protocol.

References

    1. Kahrilas PJ. Gastroesophageal relfux disease. N Engl J Med. 2008;359(16):1700–1707. doi:10.1056/NEJMcp0804684
    1. Moayyedi P, Talley N. Gastro-esophageal reflux disease. Lancet. 2006;367(9528):2086–2100. doi:10.1016/S0140-6736(06)68932-0
    1. Khan M, Santana J, Donnellan C. Medical treatment in the short term management of reflux esophagitis. Cochrane Database Syst Rev. 2007;2:CD003244.
    1. Chiba N, De Gara CJ, Wilkinson JM, et al. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology. 1997;112(6):1798–1810.
    1. Kahrilas PJ, Fennerty MB, Joelsson B. High- versus standard-dose ranitidine for control of heartburn in poorly response gastroesophgeal reflux disease: a prosptive, controlled trial. Am J Gastroenterol. 1999;94(1):92–97. doi:10.1111/j.1572-0241.1999.00777.x
    1. Donnellan C, Sharma N, Preston C. Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev. 2005;2:CD003245.
    1. Dent J, Talley NJ. Overview: initial and long-term management of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2003;17(Suppl 1):53–57. Review.
    1. Laine L, Ahnen D, McClain C, et al. Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther. 2000;14(6):651–668. Review.
    1. Yang YX, Lewis JD, Epstein S, et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296(24):2947–2953. doi:10.1001/jama.296.24.2947
    1. Garcia Rodríguez LA, Ruigómez A. Gastric acid, acid-suppressing drugs, and bacterial gastroenteritis: how much of a risk? Epidemiology. 1997;8(5):571–574.
    1. Dial S, Alrasadi K, Manonkian C, et al. Risk of Clostridium difficile among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. Cmaj. 2004;171(1):33–38.
    1. Gerson LB, Robbins AS, Garber A, et al. A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease. Am J Gastroenterol. 2000;95(2):395–407. doi:10.1111/j.1572-0241.2000.01759.x
    1. Vakil N. Review article: cost-effectiveness of different GERD management strategies. Aliment Pharmacol Ther. 2002;16(Suppl 4):79–82. Review.
    1. Tytgat GN. Review article: management of mild and severe gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2003;17(Suppl 2):52–56. Review.
    1. Hsu PI, Lu CL, Wu DC, et al. Eight weeks of esomeprazole therapy reduces symptom relapse, compared with 4 weeks, in patients with Los Angeles grade A or B erosive esophagitis. Clin Gastroenterol Hepatol. 2015;13(5):859–866. doi:10.1016/j.cgh.2014.09.033
    1. Metz DC, Howden CW, Perez MC, et al. Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis. Aliment Pharmacol Ther. 2009;29(7):742–754. doi:10.1111/j.1365-2036.2009.03954.x
    1. Sharma P, Shaheen NJ, Perez MC, et al. Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation–results from two randomized controlled studies. Aliment Pharmacol Ther. 2009;29(7):731–741. doi:10.1111/j.1365-2036.2009.03933.x
    1. Richter JE, Kahrilas PJ, Johanson J, et al; Esomeprazole Study Investigators. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol. 2001;96(3):656–665. doi:10.1111/j.1572-0241.2001.3600_b.x
    1. Schmitt C, Lightdale CJ, Hwang C, et al. A multicenter, randomized, double-blind, 8-week comparative trial of standard doses of esomeprazole (40 mg) and omeprazole (20 mg) for the treatment of erosive esophagitis. Dig Dis Sci. 2006;51(5):844–850. doi:10.1007/s10620-005-9062-4
    1. Wong WM, Lai KC, Lam KF, et al. Prevalence, clinical spectrum and health care utilization of gastro-oesophageal reflux disease in a Chinese population: a population-based study. Aliment Pharmacol Ther. 2003;18(6):595–604.
    1. Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut. 1999;45(2):172–180.
    1. Fock KM, Teo EK, Ang TL, et al. The utility of narrow band imaging in improving the endoscopic diagnosis of gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2009;7(1):54–59. doi:10.1016/j.cgh.2008.08.030
    1. Kasap E, Zeybel M, Aşık G, et al. Correlation among standard endoscopy, narrow band imaging, and histopathological findings in the diagnosis of nonerosive reflux disease. J Gastrointestin Liver Dis. 2011;20(2):127–130.
    1. Vakil N, van Zanten SV, Kahrilas P, et al; Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101(8):1900–1920. doi:10.1111/j.1572-0241.2006.00630.x
    1. Hu WHC, Lam KF, Wong YH, et al. The Hong Kong index of dyspepsia: a validated symptom severity questionnaire for patients with dyspepsia. J Gastroenterol Hepatol. 2002;17(5):545–551.
    1. Revicki DA, Crawley JA, Zodet MW, et al. Complete resolution of heartburn symptoms and health-related quality of life in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 1999;13(12):1621–1630.
    1. Remes-Troche JM, Sobrino-Cossio S, Soto-Perez JC, et al. Efficacy, safety, and tolerability of pantoprazole magnesium in the treatment of reflux symptoms in patients with gastroesophageal reflux disease (GERD): a prospective, multicenter, post-marketing observational study. Clin Drug Investig. 2014;34(2):83–93. doi:10.1007/s40261-013-0135-4
    1. Tytgat G. Long-term GERD management: the individualized approach. Drugs Today (Barc). 2006;42(Suppl B):23–29. Review.
    1. Revicki DA, Zodet MW, Joshua-Gotlib S, et al. Health-related quality of life improves with treatment-related GERD symptom resolution after adjusting for baseline severity. Health Qual Life Outcomes. 2003;29(1):73. doi:10.1186/1477-7525-1-73
    1. Kahrilas PJ, Falk GW, Johnson DA, et al; The Esomeprazole Study Investigators. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. Aliment Pharmacol Ther. 2000;14(10):1249–1258.
    1. Gralnek IM, Dulai GS, Fennerty MB, et al. Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials. Clin Gastroenterol Hepatol. 2006;4(12):1452–1458. doi:10.1016/j.cgh.2006.09.013
    1. Metz DC, Vakily M, Dixit T, et al. Review article: dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy. Aliment Pharmacol Ther. 2009;29(9):928–937. doi:10.1111/j.1365-2036.2009.03984.x
    1. Wu MS, Tan SC, Xiong T. Indirect comparison of randomised controlled trials: comparative efficacy of dexlansoprazole vs. esomeprazole in the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2013;38(2):190–201. doi:10.1111/apt.12349
    1. Sugimoto M, Furuta T. Efficacy of esomeprazole in treating acid-related diseases in Japanese populations. Clin Exp Gastroenterol. 2012;5:49–59. doi:10.2147/CEG.S23926
    1. Johnson DA, Benjamin SB, Vakil NB, et al. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety. Am J Gastroenterol. 2001;96(1):27–34. doi:10.1111/j.1572-0241.2001.03443.x
    1. Howden CW, Larsen LM, Perez MC, et al. Clinical trial: efficacy and safety of dexlansoprazole MR 60 and 90 mg in healed erosive oesophagitis - maintenance of healing and symptom relief. Aliment Pharmacol Ther. 2009;30(9):895–907. doi:10.1111/j.1365-2036.2009.04119.x
    1. Liang CM, Kuo MT, Hsu PI, et al. First-week clinical responses to dexlansoprazole 60 mg and esomeprazole 40 mg for the treat-ment of grades A and B gastroesophageal reflux disease. World J Gastroenterol. 2017;23(47):8395–8404. doi:10.3748/wjg.v23.i47.8395
    1. Smout AJPM; Gastro-oesophageal reflux disease. Pathogenesis and diagnosis In: Champion MC, Orr WC editors. Evolving Concepts in Gastrointestinal Motility. Oxford, England: Blackwell Science; 199646–63.
    1. Van Thiel DH, Gavaler JS, Stremple J. Lower esophageal sphincter pressure in women using sequential oral contraceptives. Gastroenterology. 1976;71(2):232–234.
    1. Behm BW, Peura DA. Dexlansoprazole MR for the management of gastroesophageal reflux disease. Expert Rev Gastroenterol Hepatol. 2011;5(4):439–445. doi:10.1586/egh.11.37
    1. Kukulka M, Eisenberg C, Nudurupati S. Comparator pH study to evaluate the single-dose pharmacodynamics of dual delayed-release dexlansoprazole 60 mg and delayed-release esomeprazole 40 mg. Clin Exp Gastroenterol. 2011;4:213–220. doi:10.2147/CEG.S24063
    1. Fass R, Inadomi J, Han C, et al. Maintenance of heartburn relief after step-down from twice-daily proton pump inhibitor to once-daily dexlansoprazole modified release. Clin Gastroenterol Hepatol. 2012;10(3):247–253. doi:10.1016/j.cgh.2011.11.021
    1. Suzuki H, Matsuzaki J, Okada S, et al. Validation of the GerdQ questionnaire for the management of gastro-oesophageal reflux disease in Japan. United European Gastroenterol J. 2013;1(3):175–183. doi:10.1177/2050640613485238

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj